Recent Herceptin Current Events | Herceptin News
|
|
|
Sort By:
Relevance | Page Views |
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. view more (2009-11-10)
Early-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. view more (2009-11-03)
Canadian cardiology team clears the way for lifesaving breast cancer treatment
A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. view more (2009-10-26)
Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). view more (2009-09-14)
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. view more (2009-05-15)
Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue... view more... (2009-04-07)
Light reveals breast tumor oxygen status
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient. view more (2009-04-01)
Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
New research suggests that monoclonal antibody therapy of cancer can be improved to be much more powerful than it is today, says a researcher at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center in the March 21 issue of the Lancet. view more (2009-03-20)
Nanoscopic probes can track down and attack cancer cells
A researcher has developed probes that can help pinpoint the location of tumors and might one day be able to directly attack cancer cells. view more (2009-03-16)
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). view more (2008-10-06)
Breast cancer treatment resistance linked to signaling pathway
Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development... view more... (2008-09-23)
M. D. Anderson study finds change in HER2 status after treatment with Herceptin
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. view more (2008-09-04)
CSHL scientists identify new drug target against virulent type of breast cancer
Tumor cells in a particular subset of breast cancer patients churn out too much of a protein called ErbB2 -- also often called HER2 -- which drives the cells to proliferate unchecked. Patients unlucky enough to be in this group -- about one in four -- have poorer prognoses and clinical outcomes than those who don't. view more (2008-08-26)
First step towards switching off breast cancer and leukaemia
Australian scientists have identified a way to 'switch off' a molecule, a key player in the molecular processes that trigger breast cancer and certain forms of leukaemia. view more (2008-08-11)
OHSU Cancer Instutute researchers find abnormalities in gene for melanoma
New research from the Oregon Health & Science University Cancer Institute about mutations in melanoma may bring a wellspring of hope to many patients. view more (2008-05-30)
Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers
Researchers at the University of Pennsylvania School of Medicine have shown how Argos, a fruit fly protein, acts as a ¡¥decoy' receptor, binding growth factors that promote the progression of cancer. view more (2008-05-29)
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment. view more (2008-04-18)
Double binding sites on tumor target may provide future combination therapy
Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer. view more (2008-04-09)
New study of targeted therapies for breast cancer -- model for global clinical trials
Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research. view more (2008-02-29)
Manchester researchers announce new methods of beating breast cancer
University of Manchester researchers will reveal new ways of controlling and treating breast cancer at the National Cancer Research Institute conference in Birmingham today (Monday 1 October 2007). view more (2007-10-02)
|
|
|
|
Sort By:
Relevance | Page Views |
|
